Clinical Trial

Decolonization of Gram-negative Multi-resistant Organisms (MDRO) with Donor Microbiota (FMT)

Study acronym: DEKODON
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Colonization by Multiple Drug Resistant Organisms (MDROs) during patient hospitalization requires expensive isolation measures and renders the return or transfer to other departments or institutions often impossible. Currently there is no specific treatment available. Patients have to wait for spontaneous clearance which can take months or does not happen at all. The study will test the effect of Fecal Microbiota Transfer (FMT) on gut MDRO colonization. The focus will be on patients with a long-term colonization by Gram-negative bacteria for which isolation is warranted. Participants will be randomized into two treatment groups; allogenic FMT versus autologous FMT. A third group of participants will be monitored but will not receive an FMT. Decolonization rate will be compared one month after treatment. Additionally gut microbial composition will be studied up to one year after FMT.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-12-03; most recent amendment 2024-09-05.
Status change: Not Yet Recruiting → Recruiting 2020-01-08
Trial Details
NCT Number NCT04188743
Lead Sponsor University Hospital, Ghent
Collaborators: Research Foundation Flanders
Conditions Resistance Bacterial
Enrollment 150 participants
Start Date 2019-12-18
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19